Get started
Author

A. Insa

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
2014 · T. Moran, J. Wei, et al. · Annals of Oncology · 32
PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
2022 · M. Provencio, R. Serna, et al. · Journal of Thoracic Oncology · 29
PDF
Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme
2022 · M. T. Martínez, S. Moragon, et al. · Cancer Control · 5
MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
2022 · A. Romero, R. Serna, et al. · Journal of Thoracic Oncology · 5
MA01.08 Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer (NADIM Trial)
2024 · M. Provencio, E. Nadal, et al. · Journal of Thoracic Oncology · 3
PDF
EP08.02-149 Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab
2022 · V. Albarrán-Artahona, J. Torres-Jiménez, et al. · Journal of Thoracic Oncology · 2
PDF
P1.199: Persistent N2 After Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer: Insights From Three Prospective Cohorts
2026 · M. Provencio, B. Massutí, et al. · Journal of Thoracic Oncology
MO06.09: Role of PET/CT in the Neoadjuvant Chemoimmunotherapy Approach for Resectable NSCLC: Results From the NADIM II and REAL-NADIM Trials
2026 · R. Jimeno, A.V. Ospina, et al. · Journal of Thoracic Oncology
P3.122: B Cell Density in Mature Tlss Is Associated With Pathological Complete Response After Neoadjuvant Chemoimmunotherapy
2026 · J.M. Gutiérrez-Escobedo, B. Sierra-Rodero, et al. · Journal of Thoracic Oncology
PT1.07.04: ARIAN, a Phase III, Randomized Study of Adjuvant Treatment With Sacituzumab and Zimberelimab in Resected Patients
2026 · V. Calvo, R. López Castro, et al. · Journal of Thoracic Oncology
P3.173: Gut Microbiome Taxa Associated With Response to Chemo-Immunotherapy in NSCLC: A Multi-Method Differential Abundance Analysis
2026 · R. Serna-Blasco, A. Rodriguez Festa, et al. · Journal of Thoracic Oncology
P3.130: Microbiome Functional Signatures as Potential Biomarkers and Mechanistic Modulators of Response to Neoadjuvant Therapy in NSCLC
2026 · R. Serna-Blasco, A. San Martin Doblado, et al. · Journal of Thoracic Oncology
P3.12.30 Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features
2025 · S. Torresan, C. Salva de Torres, et al. · Journal of Thoracic Oncology
MA06.03 Pharmacoeconomic Analysis of NADIM 2 Trial: Cost-Effectiveness of Perioperative Chemo-Immunotherapy in Resectable Stage III NSCLC
2025 · B. Massuti, E. Nadal, et al. · Journal of Thoracic Oncology
EP04.01-002 Costs of Locoregional and Metastatic Recurrences in Patients with Resectable Stage II-III NSCLC in Spain
2022 · J.d.C. Carpeño, A. Insa, et al. · Journal of Thoracic Oncology
PDF
P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
2022 · S. Hernandez, J.L. Rodriguez Carrillo, et al. · Journal of Thoracic Oncology
PDF
OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
2022 · M. Casarrubios, A. Cruz-Bermúdez, et al. · Journal of Thoracic Oncology
Works count: 17
Citation count: 76
H-index: 4
I10-index: 2
Year
Topic
Type